New CMV Native Antigen

Online, January 3, 2012 (Newswire.com) - The antigen has been manufactured in response to the in-vitro diagnostics (IVD) industry's requirement for a cost effective antigen which can demonstrate a high affinity for not only IgG but more importantly, for IgM. This latest antigen from NAC's rapidly increasing portfolio also minimizes cross-reactivity and lot to lot variation. The company is well equipped to meet an anticipated high volume requirement from IVD manufacturers who major in this field.

Presently, CMV infection is mostly controlled in immune compromised patients by available antiviral drugs, yet it continues to maintain its role as one of the most dangerous infectious agents for the unborn infant. Primary infection is consistently associated with the presence of a virus specific IgM antibody response. Use of NAC's CMV purified native antigen will aid in improving serology based assays for early detection.

At The Native Antigen Company, we specialise in the isolation and purification of native viral and bacterial antigens. Our market focus is the infectious disease segment of the in-vitro diagnostics industry. Our scientific and production team based in Oxford, UK has the scope to produce almost any native antigen, from small to bulk. We focus on the more challenging to produce antigens and in particular those which lead to significant improvements in the early detection of disease.

In addition, we offer toxins and toxoids to the pharma and research community, as well as an Adenovirus purification capability and a screening service for anti-cancer drug compounds.

We offer a direct service on a worldwide basis.

Alongside its native antigen main focus, The Native Antigen Company offers several services such as Adenovirus purification and drug testing. Due to many years of research into viral vectors and oncolytic agents, we have gained considerable expertise in performing these services and assays, and have written and optimised the latest protocols in these areas. We aim to meet the specific needs of those companies that want specific contract research projects carrying out, but at cost-effective prices.

For more information please contact Andrew Maxwell, The Native Antigen Company on +44 (0)1869 238067, [email protected] or visit www.thenativeantigencompany.com